Get the latest news, insights, and market updates on OCUL (Ocular Therapeutix, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes
Ocular Therapeutix Inc. (NASDAQ:OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration (AMD). The stock is trading lower as data did not meet investor expectations. STAT News reported that Axpaxli's durability advantage over the active control was smaller than investors had anticipated, potentially raising questions about its commercial outlook in wet age-related macular degeneration Feb 19, 2026 - $OCUL
1 Volatile Stock for Long-Term Investors and 2 Facing Challenges
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. Feb 19, 2026 - $OCUL
Ocular Therapeutix stock news: Why positive data led to a 25% drop
Investing.com -- Ocular Therapeutix (NASDAQ:OCUL) stock fell 25% Tuesday after the company reported top-line results from its Phase 3 SOL-1 superiority trial for Axpaxli in wet age-related macular degeneration (AMD). EyePoint (NASDAQ:EYPT) shares dropped 15%, while Regeneron Pharmaceuticals (NASDAQ:REGN) shares were flat. Feb 17, 2026 - $OCUL
Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD
First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001), compared to aflibercept (2 mg) arm Rescue-free rates in the A Feb 17, 2026 - $OCUL
Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known Feb 13, 2026 - $OCUL
Ocular Therapeutix Equity Grants Balance Growth Plans And Dilution Concerns
Ocular Therapeutix granted equity inducement awards to new employees to support its clinical development and commercialization expansion. The awards were made as part of ongoing hiring to build out the company’s pipeline and commercial capabilities. The announcement signals continued organizational growth that may be relevant for investors tracking NasdaqGM:OCUL. Ocular Therapeutix, trading on NasdaqGM under the ticker OCUL, last closed at $9.03. The shares are up 6.1% over the past week... Feb 11, 2026 - $OCUL
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to five newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The in Feb 6, 2026 - $OCUL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple